Unitree Robotics appears positioned to become the first major humanoid robot company to go public in 2026. The Shanghai-based robotics manufacturer has an IPO review scheduled for June 1, 2026, on China’s Stock Exchange STAR Market, with plans to raise 4.2 billion yuan (approximately $610-620 million). This timing, combined with the company’s status as the world’s largest humanoid robot seller, gives Unitree a substantial lead over competitors globally who are either in earlier stages of IPO preparation or have no confirmed 2026 listing dates.
The race to become the first humanoid robot IPO reflects a broader shift in venture capital and public markets: autonomous robotics has moved from research labs to commercial production. Unitree’s planned June review date, announced through sources including Rest of World and financial platforms, puts the company on track to list before other contenders like Deep Robotics (China), Agibot (Hong Kong), and Western companies such as Boston Dynamics. The financial metrics behind Unitree’s IPO application reveal why investors and markets are moving so quickly on humanoid robotics.
Table of Contents
- What Makes Unitree Robotics the Likely First Humanoid Robot IPO in 2026?
- How Do China’s Regulatory Pathways Accelerate IPO Timelines Compared to Western Markets?
- What Do Unitree’s Financial Metrics Reveal About Humanoid Robot Market Demand?
- Why Is Shanghai’s Stock Exchange the Preferred Destination Over Hong Kong or the United States?
- What Regulatory or Market Risks Could Prevent These IPOs From Completing in 2026?
- How Does Agibot’s Hong Kong Play Differ From the Chinese Mainland Approach?
- How Do Valuations and IPO Timelines Compare Between Confirmed Listings and Companies Without 2026 Dates?
What Makes Unitree Robotics the Likely First Humanoid Robot IPO in 2026?
Unitree’s path to the market is distinguished by scale and profitability. In 2025, the company generated 1.71 billion yuan ($250 million) in revenue, a 336 percent increase year-over-year, while net profit reached 600 million yuan ($90 million), climbing 674.3 percent. These growth rates are rare even among venture-backed robotics firms; most robotics startups operate at losses while scaling production. Unitree’s profitability at scale demonstrates that there is genuine commercial demand for humanoid robots, not merely speculative hype from investors betting on future applications.
The company’s market position stems from its product lineup, which includes both low-cost bipedal robots aimed at research and development teams and more advanced models for industrial tasks. Unitree’s G1 humanoid robot, for example, has been used in logistics centers and light manufacturing settings. The diversity of applications and the company’s ability to serve customers ranging from universities to manufacturing facilities helped generate the revenue growth that attracted the attention of Shanghai’s stock exchange regulators. Few humanoid robot companies outside of China have achieved this volume of real-world deployment.
How Do China’s Regulatory Pathways Accelerate IPO Timelines Compared to Western Markets?
China’s Stock Exchange STAR Market (Science and Technology Innovation Board) was designed specifically to fast-track listings for technology companies, including robotics firms, without requiring the years of profitability that traditional mainland Chinese exchanges demand. Unitree’s IPO review in June reflects this expedited pathway. By contrast, Western companies seeking to go public must navigate the U.S. Securities and Exchange Commission’s disclosure requirements, which demand detailed financial projections and competitive analysis.
boston Dynamics, despite being owned by Hyundai and having decades of R&D investment, has not announced a 2026 IPO date, partly because the regulatory environment for industrial robotics companies in the U.S. requires more extensive operational history and clearer revenue models. The STAR Market advantage comes with a caveat: Chinese regulators prioritize innovation metrics alongside financial performance, which means Unitree’s growth rate matters as much as its absolute profitability. If the company’s revenue growth were to decelerate significantly before the listing, the regulators could delay the review. Additionally, geopolitical tensions around semiconductor exports and trade restrictions on advanced manufacturing equipment could theoretically introduce delays, though Unitree’s primary business is in assembly and software rather than chip design.
What Do Unitree’s Financial Metrics Reveal About Humanoid Robot Market Demand?
The 336 percent revenue increase year-over-year suggests that customer demand for humanoid robots is moving beyond speculative interest into genuine procurement. Companies in logistics, manufacturing, and research institutions are placing orders and paying for units. The 674 percent profit increase is even more significant because it indicates that Unitree is not merely growing revenue through discounting or unsustainable pricing; the company is improving its margins as it scales. This pattern typically emerges when a manufacturer solves production bottlenecks, secures long-term supply contracts for components, and builds operational efficiency.
However, it is worth noting that humanoid robotics remains a nascent market globally, with total addressable market estimates varying widely depending on assumptions about adoption rates. Unitree’s 1.71 billion yuan revenue ($250 million annually) is substantial for a robotics startup, but it represents a tiny fraction of the global robotics market, which includes industrial arms, mobile robots, and service robots totaling tens of billions of dollars. If Unitree’s growth rates plateau after going public—a common pattern for companies that have saturated their initial markets—the stock could face pressure. investors will be watching closely to see whether the company can diversify its customer base beyond China.
Why Is Shanghai’s Stock Exchange the Preferred Destination Over Hong Kong or the United States?
The STAR Market offers Unitree several advantages over listing on the Hong Kong Stock Exchange or U.S. Nasdaq. First, listing in Shanghai gives the company direct access to domestic Chinese capital, which has a strong appetite for technology and innovation-focused investments. Second, regulatory approval timelines are faster. Unitree’s June review date suggests a pathway to listing within months rather than the year-plus process typical in the U.S.
Third, Chinese exchanges have become more accepting of pre-profitability or lower-profit-margin technology companies, which allows firms to reinvest earnings into R&D rather than distribute profits to shareholders. This contrasts sharply with Agibot’s planned Hong Kong listing, which is targeting Q3 2026 and a valuation of HK$40-50 billion ($5.1-6.4 billion). Agibot’s later timeline reflects the more stringent financial scrutiny applied by Hong Kong regulators and the larger pool of competing companies seeking capital there. The tradeoff is that Agibot, by listing in Hong Kong, gains access to international investor pools and avoids some of the regulatory unpredictability that can affect mainland Chinese stocks. Neither market is objectively “better”; the choice reflects strategic decisions about which investor base the company wishes to serve and how much capital it needs to raise.
What Regulatory or Market Risks Could Prevent These IPOs From Completing in 2026?
Geopolitical tensions surrounding advanced manufacturing and AI capabilities represent an ongoing risk. If export restrictions on robotics components intensify or if U.S. or European regulators impose sanctions on Chinese robotics companies, Unitree’s IPO could face delays or valuations pressure. Additionally, a broader market downturn in tech stocks—which happened multiple times between 2022 and 2024—could cause regulators to pause new IPO reviews as a precaution.
China’s stock market has experienced several periods of volatility tied to macroeconomic policy shifts, and Unitree’s June review date means the listing decision will occur amid whatever market conditions exist at that moment. Another risk specific to humanoid robotics is the pace of technological innovation. If a competitor—whether Boston Dynamics, Tesla with its Optimus project, or another firm—announces a significant breakthrough in mobility, dexterity, or autonomy, it could raise questions about Unitree’s technological differentiation. Conversely, if any of these companies announce safety incidents, regulatory violations, or failed commercial deployments, it could cast doubt on the entire sector’s readiness for large-scale adoption. Deep Robotics, which is still in IPO tutoring (expected to complete in June 2026 before submitting its application), faces similar timing pressure and uncertainty.
How Does Agibot’s Hong Kong Play Differ From the Chinese Mainland Approach?
Agibot, a Shanghai-based humanoid robot company, is planning a Hong Kong Stock Exchange listing with a target valuation of HK$40-50 billion ($5.1-6.4 billion) in Q3 2026. This later timeline compared to Unitree’s June review reflects Agibot’s smaller scale and the different regulatory environment in Hong Kong. The Hong Kong exchange attracts both Asian and international investors, which can support higher valuations for companies with clear paths to global expansion.
Agibot’s strategy may involve building a business case that emphasizes international market opportunity rather than pure domestic Chinese growth. The Q3 2026 target also offers a strategic advantage: by listing after Unitree, Agibot can observe investor appetite for humanoid robot IPOs and adjust its valuation expectations accordingly. If Unitree’s IPO is oversubscribed and the stock price jumps on the first day, Agibot benefits from a stronger comparable and can pursue a higher valuation. Conversely, if investor demand is tepid, Agibot has time to strengthen its financial story or delay further.
How Do Valuations and IPO Timelines Compare Between Confirmed Listings and Companies Without 2026 Dates?
Unitree’s 4.2 billion yuan (~$610-620 million) fundraising target, combined with assumed pre-IPO valuations, suggests an enterprise value in the range of 8-12 billion yuan (approximately $1.2-1.8 billion). Agibot’s planned HK$40-50 billion valuation ($5.1-6.4 billion) is significantly higher, reflecting either higher expected revenue, stronger intellectual property claims, or investor expectations about the Hong Kong market. These valuations reveal how much uncertainty and optimism still surrounds humanoid robotics: valuations can vary five-fold based on location, investor base, and perceived competitive advantages. By contrast, companies without confirmed 2026 dates—Boston Dynamics (no official date announced, possible 2027), Figure AI (valued at $39 billion in private funding as of September 2025 but no IPO announcement), and Tesla Optimus (no separate IPO planned, with mass production targeted for Q3 2026)—operate in a different capital environment.
Boston Dynamics, despite its pioneering research, has not articulated a clear commercialization path that would satisfy U.S. stock market investors. Figure AI remains private, though its massive valuation suggests investors expect a future IPO or acquisition at a premium price. Tesla’s Optimus is treated as a division of Tesla rather than a separate company, meaning investors gain exposure through Tesla stock rather than a dedicated humanoid robot IPO.
- —
